SOFYAN AMRABAT arrived at Manchester United with a recurring back injury which had hampered his World Cup.
The midfielder joined Old Trafford from Fiorentina on a deadline-day loan deal.
But according to The Athletic, United detected a minor back injury in Amrabat's medical.
The Moroccan had revealed he received pain-killing injections just to play in the round of 16 against Spain.
Following a knock to Mason Mount which sidelined the summer signing, United were forced into the market for a new midfielder.
But talks to sign Amrabat were not plane sailing.
READ MORE MAN UTD NEWS
Arsenal fan who headbutted Keane unmasked as dad who ‘broke nose’ in attack
Get £20 in free bets when you stake £5 on football with Ladbrokes
It is claimed Fiorentina wanted a total package worth near £30million — an £8.5m loan fee, £17.1m after 15 appearances plus £4.2m in add-ons.
United only offered £2.5m for the loan, which was rejected and left the Serie A club short of patience.
The club's director of football negotiations Matt Hargreaves was left to resurrect the deal after being told it was off.
Amrabat, 27, was hellbent on a move to Manchester and even switched to the same agency as manager Erik ten Hag to get it done.
Most read in Football
Southgate 'sets date to QUIT England as FA line up swoop forGuardiola'
Arsenal fan who headbutted Keane unmasked as dad who 'broke nose' in attack
Liverpool offered world-record £215M for Salah transfer by Al-Ittihad
International footballer, 26, shot dead and 7 others hurt in horror gun attack
FREE BETS – BEST BETTING OFFERS AND BONUSES NEW CUSTOMERS
Eventually, the two clubs agreed on an £8.5m loan fee with the option to make the move permanent for £17.1m.
Amrabat has not played all season, not because of injury but as Fiorentina wanted the player to make a decision on his future.
But it remains to be seen how his back problem will effect the start of his season.
Rasmus Hojlund came off the bench in United's 3-1 loss at Arsenal over the weekend having also joined with a back injury.
Source: Read Full Article